Generics and biosimilars will lead to decline in colorectal cancer market from $8.3 billion in 2011 to $7.8 billion in 2021

Through 2021, growth in the market for colorectal cancer (CRC) treatments will decline in the face of generic competition for a key cytotoxic agent, oxaliplatin (Sanofi’s Eloxatin/Eloxatine, Yakult Honsha’s Elplat), as well as the entry of biosimilar competitors for key targeted biological agents, according to a new report from Decision Resource.

The CRC market totaled $8.3 billion in 2011 and is expected to decrease to $7.8 billion in 2021 in the USA, France, Germany, Italy, Spain, the UK and Japan, the report forecasts.

The Pharmacor Colorectal Cancer advisory service also finds that Genentech/Roche/Chugai’s Avastin will be minimally challenged as the sales leader in the CRC market over the next 10 years. Avastin (bevacizumab) will dominate the CRC market with total sales hovering around $2.5 billion, comprising nearly one-third of total CRC treatment sales in 2021, despite erosion from biosimilar versions and launches of new angiogenesis inhibitors Zaltrap (ziv-aflibercept, from Sanofi/Regeneron) and ramucirumab (ImClone Systems/Eli Lilly’s IMC-1121B).